NEWS
AMETEK, Inc. has acquired Atlas Material TestingTechnology LLC. Atlas’ products and servicesare used by their customers in both newproduct development and quality assuranceapplications, to assess product performance,reliability and compliance with industry standardsand specifications. The company explainsthat these instruments test the effects ofweathering by simulating exposure to sunlight,temperature, moisture and corrosion. “Atlas isan excellent addition to AMETEK. It is the clearglobal leader in this niche market and enjoysan excellent reputation with its customers andinternational standards setting organizations.Atlas provides us with another growth platformin the highly attractive materials testing equipmentmarket and broadens our presence inthe fast-growing photovoltaic testing market”notes Frank S. Hermance, AMETEK Chairmanand Chief Executive Officer.
www.ametek.com
EUROPEAN CENTRE FOR CHIRALITY
The European Centre for Chirality (EC2) is basedin Belgium at the University of Antwerp andGhent University and is an exclusive alliancewith BioTools Inc. Together the three organizationsare the European Centre for Chirality. It isa unique blend of scientific expertise using theconsiderable knowledge and know-how withinEC2 to provide analytical services for chiral moleculesusing techniques of Vibrational CircularDichorism and Raman Optical activity collectivelyknown as Vibrational Optical Activity.
www.btools.com
SANOFI-AVENTIS SENDS LETTER TOGENZYME SEEKING CLARIFICATIONON POTENTIAL BOARD ACTIONS
Sanofi-aventis has announced that it has senta letter to Genzyme Corporation requestingthat Genzyme clarify its position on a numberof potential Board actions raised in Genzyme’sSchedule 14D-9. Sanofi-aventis’ letter also notesthat it is encouraged by Genzyme’s decisionto “probe and evaluate alternatives” includingcontacting third parties but observes thatsanofi-aventis has not been contacted by Genzymeor its advisors. Sanofi-aventis continues toremain interested in working with Genzyme ona constructive basis and is committed to a mutuallyagreeable transaction. Reader can haveaccess to the full text of the letter that was sentto Genzyme, which is also being filed with theU.S. Securities and Exchange Commission.
en.sanofi-aventis.com
